Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicus Pharma Ltd. SEC filings document material-event reporting for a clinical-stage life sciences and biotechnology company incorporated in Ontario. The filings identify the company's one-segment operating model and record capital-structure activity involving common shares, shelf registration statements, at-the-market offering arrangements and a standby equity purchase agreement.
Recent Form 8-K disclosures also cover unregistered equity sales, debenture financing with subsidiary guaranties, debt repayment mechanics, amendments to equity distribution agreements and listing-compliance notices. These filings frame the company's financing arrangements, governance obligations, securities registration activity and exchange-status disclosures.
Medicus Pharma Ltd. entered into a secured note financing totaling $12,864,225 and $10,000,000 and disclosed noncompliance with Nasdaq’s market value listing standard.
The company issued a Secured Promissory Note A-1 with an 8.75% interest rate, an original issue discount of $834,225, and received $12,000,000 in cash with about $2,500,000 used to repay an existing debenture. A separate B Note of $10,000,000 at 5% interest was funded into a controlled deposit account and can be exchanged into A-type notes, releasing cash as redemptions occur. Both notes mature in 18 months and carry prepayment premiums of 110% or 115%, monthly and trading-based redemption features, and event-driven balance step-ups.
Nasdaq notified the company that its Market Value of Listed Securities has been below $35,000,000 for 30 consecutive business days and that it also fails alternative equity and income standards. Medicus has 180 days, until November 16, 2026, to regain compliance or face potential delisting, though its shares and warrants continue trading under “MDCX” and “MDCXW.”
Medicus Pharma Ltd. entered into a secured note financing totaling $12,864,225 and $10,000,000 and disclosed noncompliance with Nasdaq’s market value listing standard.
The company issued a Secured Promissory Note A-1 with an 8.75% interest rate, an original issue discount of $834,225, and received $12,000,000 in cash with about $2,500,000 used to repay an existing debenture. A separate B Note of $10,000,000 at 5% interest was funded into a controlled deposit account and can be exchanged into A-type notes, releasing cash as redemptions occur. Both notes mature in 18 months and carry prepayment premiums of 110% or 115%, monthly and trading-based redemption features, and event-driven balance step-ups.
Nasdaq notified the company that its Market Value of Listed Securities has been below $35,000,000 for 30 consecutive business days and that it also fails alternative equity and income standards. Medicus has 180 days, until November 16, 2026, to regain compliance or face potential delisting, though its shares and warrants continue trading under “MDCX” and “MDCXW.”
Medicus Pharma Ltd. reports first-quarter 2026 results, with a net loss of $9.0M and no revenue as it advances its drug pipeline. Operating expenses rose sharply, driven by higher general and administrative spending and increased research and development, including work on Teverelix and SkinJect.
Cash and cash equivalents were $6.4M as of March 31, 2026, after using $9.0M in operating cash during the quarter and raising equity through a standby equity purchase agreement and at-the-market sales. Management discloses substantial doubt about the company’s ability to continue as a going concern.
The company expanded its at-the-market program and continued to rely on Yorkville-financed debentures and equity facilities, while also reporting positive Phase 2 data for its SkinJect microneedle therapy and FDA clearance to begin a Phase 2b study of Teverelix in advanced prostate cancer.
Medicus Pharma Ltd. reports first-quarter 2026 results, with a net loss of $9.0M and no revenue as it advances its drug pipeline. Operating expenses rose sharply, driven by higher general and administrative spending and increased research and development, including work on Teverelix and SkinJect.
Cash and cash equivalents were $6.4M as of March 31, 2026, after using $9.0M in operating cash during the quarter and raising equity through a standby equity purchase agreement and at-the-market sales. Management discloses substantial doubt about the company’s ability to continue as a going concern.
The company expanded its at-the-market program and continued to rely on Yorkville-financed debentures and equity facilities, while also reporting positive Phase 2 data for its SkinJect microneedle therapy and FDA clearance to begin a Phase 2b study of Teverelix in advanced prostate cancer.
Medicus Pharma Ltd. Schedule 13G/A discloses that Ajay Raju (including related entities) beneficially owns 2,031,250 Common Shares, representing 3.7% of the class. The filing states 55,164,465 Common Shares outstanding as of April 30, 2026.
The holding consists of 2,000,000 shares held of record by 215 Capital Togo PHL Fund I, LP plus 31,250 shares underlying exercisable options. Voting and dispositive power is reported via Togo PHL Management LLC and Ajay Raju as managing member.
Medicus Pharma Ltd. Schedule 13G/A discloses that Ajay Raju (including related entities) beneficially owns 2,031,250 Common Shares, representing 3.7% of the class. The filing states 55,164,465 Common Shares outstanding as of April 30, 2026.
The holding consists of 2,000,000 shares held of record by 215 Capital Togo PHL Fund I, LP plus 31,250 shares underlying exercisable options. Voting and dispositive power is reported via Togo PHL Management LLC and Ajay Raju as managing member.
Medicus Pharma Ltd. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, governance and compensation. The filing confirms a nine‑member board with six standing committees and extensive biographies for each director and senior executive.
The company reports an aggregate market value of non‑affiliate common shares of approximately $28.3 million as of June 30, 2025, and 41,818,092 common shares outstanding as of April 15, 2026. Compensation tables disclose 2025 pay for four named executive officers, including salary, option awards and other compensation, along with option holdings and vesting values.
Medicus Pharma Ltd. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, governance and compensation. The filing confirms a nine‑member board with six standing committees and extensive biographies for each director and senior executive.
The company reports an aggregate market value of non‑affiliate common shares of approximately $28.3 million as of June 30, 2025, and 41,818,092 common shares outstanding as of April 15, 2026. Compensation tables disclose 2025 pay for four named executive officers, including salary, option awards and other compensation, along with option holdings and vesting values.
Medicus Pharma Ltd. amended its Equity Distribution Agreement with Maxim Group and Yorkville Securities to expand its at-the-market stock sales program from $15,349,674 to up to $50,000,000. The company has already raised about $11.5 million under this program.
Medicus also received a Nasdaq notice that its shares traded below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq’s minimum bid price rule. The company has 180 days, until October 19, 2026, for its closing bid to reach at least $1.00 for 10 straight business days to regain compliance.
Medicus Pharma Ltd. amended its Equity Distribution Agreement with Maxim Group and Yorkville Securities to expand its at-the-market stock sales program from $15,349,674 to up to $50,000,000. The company has already raised about $11.5 million under this program.
Medicus also received a Nasdaq notice that its shares traded below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq’s minimum bid price rule. The company has 180 days, until October 19, 2026, for its closing bid to reach at least $1.00 for 10 straight business days to regain compliance.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a stock option grant covering 25,000 common shares. The options were awarded at an exercise price of $0.50 per share, carry no upfront cost, and expire on March 27, 2031. Following this grant, she holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a stock option grant covering 25,000 common shares. The options were awarded at an exercise price of $0.50 per share, carry no upfront cost, and expire on March 27, 2031. Following this grant, she holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Raju Ajay received a stock option grant for 25,000 common shares. The award gives him the right to buy 25,000 shares at an exercise price of $0.50 per share. The option becomes exercisable on March 26, 2027 and expires on March 27, 2031, and his directly held option position reported in this filing totals 25,000 derivative securities.
Medicus Pharma Ltd. director Raju Ajay received a stock option grant for 25,000 common shares. The award gives him the right to buy 25,000 shares at an exercise price of $0.50 per share. The option becomes exercisable on March 26, 2027 and expires on March 27, 2031, and his directly held option position reported in this filing totals 25,000 derivative securities.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options as part of his compensation. The award covers 125,000 stock options, each exercisable for one common share at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this award, Faisal holds 125,000 stock options directly.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options as part of his compensation. The award covers 125,000 stock options, each exercisable for one common share at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this award, Faisal holds 125,000 stock options directly.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 25,000 underlying common shares. The options have an exercise price of $0.50 per share and can first be exercised on March 26, 2027.
These options expire on March 27, 2031. Following this grant, May Sara R. holds derivative securities representing 25,000 common shares, reflecting a compensation-related award rather than an open-market purchase.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 25,000 underlying common shares. The options have an exercise price of $0.50 per share and can first be exercised on March 26, 2027.
These options expire on March 27, 2031. Following this grant, May Sara R. holds derivative securities representing 25,000 common shares, reflecting a compensation-related award rather than an open-market purchase.
Medicus Pharma Ltd. director Patrick J. Mahaffy received a compensation-related stock option grant, not an open-market trade. He was granted options to acquire 25,000 common shares at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this grant, he holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Patrick J. Mahaffy received a compensation-related stock option grant, not an open-market trade. He was granted options to acquire 25,000 common shares at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this grant, he holds options for 25,000 shares directly.